1. World Health Organization. Report of a WHO consultation: definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus Geneva: World Health Organization, Department of Noncommunicable Disease Surveillance; 1999.
2. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010;1:212-28.
Article PubMed PMC
3. Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int 2020;11:165-223.
Article PubMed PMC PDF
4. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461-98.
Article PubMed PDF
5. Hur KY, Moon MK, Park JS, Kim SK, Lee SH, Yun JS, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J 2021;45:461-81.
Article PubMed PMC PDF
6. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 2022;45(Suppl 1):S144-74.
7. Chan JC, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The Lancet commission on diabetes: using data to transform diabetes care and patient lives. Lancet 2021;396:2019-82.
Article PubMed
8. Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 1997;314:1666-74.
Article PubMed PMC
9. Agewall S, Wikstrand J, Samuelsson O, Persson B, Andersson OK, Fagerberg B. The efficacy of multiple risk factor intervention in treated hypertensive men during long-term follow up. Risk Factor Intervention Study Group. J Intern Med 1994;236:651-9.
Article PubMed
10. Kempler P. Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diabetes Res Clin Pract 2005;68 Suppl 1:S43-7.
Article
11. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
Article PubMed
12. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
Article PubMed
13. Tanner M. In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years. Ann Intern Med 2020;172:JC41.
Article PubMed
14. Yagyu H, Shimano H. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. J Diabetes Investig 2022;13:1472-88.
Article PubMed PMC PDF
15. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156-67.
Article PubMed PMC
16. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (JDOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:951-64.
PubMed
17. Sasso FC, Pafundi PC, Simeon V, De Nicola L, Chiodini P, Galiero R, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol 2021;20:145.
Article PubMed PMC PDF
18. Shikata K, Haneda M, Ninomiya T, Koya D, Suzuki Y, Suzuki D, et al. Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan). J Diabetes Investig 2021;12:207-16.
Article PubMed PMC PDF
19. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
Article PubMed
20. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 2004;53 Suppl 3:S39-47.
PubMed
21. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9.
Article PubMed
22. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31:1510-5.
PubMed PMC
23. Gaede P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298-307.
Article PubMed PMC PDF
24. Gaede P, Oellgaard J, Kruuse C, Rossing P, Parving HH, Pedersen O. Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study. Diabetologia 2019;62:1575-80.
Article PubMed PMC PDF
25. Oellgaard J, Gaede P, Rossing P, Rorth R, Kober L, Parving HH, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61:1724-33.
Article PubMed PMC PDF
26. Oellgaard J, Gaede P, Rossing P, Persson F, Parving HH, Pedersen O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int 2017;91:982-8.
Article PubMed
27. Gaede J, Oellgaard J, Ibsen R, Gaede P, Nortoft E, Parving HH, et al. A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study. Diabetologia 2019;62:147-55.
Article PubMed PMC PDF
28. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G, et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24 Suppl 3:S6-11.
Article PubMed PDF
29. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009;59:43-8.
Article PubMed PMC
30. Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL, et al. The ADDITION-Cambridge trial protocol: a cluster: randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009;9:136.
Article PubMed PMC PDF
31. Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S, et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 2010;11:16.
Article PubMed PMC PDF
32. Sandbæk A, Griffin SJ, Sharp SJ, Simmons RK, Borch-Johnsen K, Rutten GE, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study. Diabetes Care 2014;37:2015-23.
PubMed
33. Griffin SJ, Rutten GE, Khunti K, Witte DR, Lauritzen T, Sharp SJ, et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7:925-37.
Article PubMed
34. Preiss D, Sattar N. The case for diabetes screening: ADDITION-Europe. Lancet 2011;378:106-8.
Article PubMed
35. Simmons RK, Sharp SJ, Sandbaek A, Borch-Johnsen K, Davies MJ, Khunti K, et al. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes?: findings from the ADDITION-Europe cluster-randomized trial. Diabet Med 2012;29:e409-16.
Article PubMed PMC PDF
36. Johansen NB, Charles M, Vistisen D, Rasmussen SS, Wiinberg N, Borch-Johnsen K, et al. Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2012;35:2207-14.
PubMed PMC
37. Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screendetected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2011;34:2244-9.
PubMed PMC
38. Charles M, Fleischer J, Witte DR, Ejskjaer N, Borch-Johnsen K, Lauritzen T, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia 2013;56:101-8.
Article PubMed PDF
39. Koekkoek PS, Ruis C, van den Donk M, Biessels GJ, Gorter KJ, Kappelle LJ, et al. Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes: the ADDITION-Netherlands study: a cluster-randomized trial. J Neurol Sci 2012;314:71-7.
Article PubMed
40. Tao L, Wilson EC, Wareham NJ, Sandbaek A, Rutten GE, Lauritzen T, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screendetected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med 2015;32:907-19.
Article PubMed PMC PDF
41. Thoolen BJ, de Ridder DT, Bensing JM, Gorter KJ, Rutten GE. Psychological outcomes of patients with screen-detected type 2 diabetes: the influence of time since diagnosis and treatment intensity. Diabetes Care 2006;29:2257-62.
PubMed
42. van den Donk M, Gorter KJ, Rutten GE. No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients: the ADDITIONNetherlands study. Qual Life Res 2010;19:509-13.
Article PubMed PMC PDF
43. Van den Donk M, Griffin SJ, Stellato RK, Simmons RK, Sandbaek A, Lauritzen T, et al. Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. Diabetologia 2013;56:2367-77.
Article PubMed PMC PDF
44. Kuznetsov L, Griffin SJ, Davies MJ, Lauritzen T, Khunti K, Rutten GE, et al. Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: a cross-sectional analysis of the ADDITION-Europe trial cohort. Diabetes Res Clin Pract 2014;104:281-7.
Article PubMed
45. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012;380:1741-8.
Article PubMed PMC
46. Dalsgaard EM, Sandbaek A, Griffin SJ, Rutten GE, Khunti K, Davies MJ, et al. Patient-reported outcomes after 10-year follow-up of intensive, multifactorial treatment in individuals with screen-detected type 2 diabetes: the ADDITION-Europe trial. Diabet Med 2020;37:1509-18.
Article PubMed PMC PDF
47. Ueki K, Sasako T, Kato M, Okazaki Y, Okahata S, Katsuyama H, et al. Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Res Care 2016;4:e000123.
Article PubMed PMC
48. Yazaki Y, Kadowaki T. Combating diabetes and obesity in Japan. Nat Med 2006;12:73-4.
Article PubMed PDF
49. Sakane N, Kotani K, Takahashi K, Sano Y, Tsuzaki K, Okazaki K, et al. Effects of telephone-delivered lifestyle support on the development of diabetes in participants at high risk of type 2 diabetes: J-DOIT1, a pragmatic cluster randomised trial. BMJ Open 2015;5:e007316.
Article PubMed PMC
50. Hayashino Y, Suzuki H, Yamazaki K, Goto A, Izumi K, Noda M. A cluster randomized trial on the effect of a multifaceted intervention improved the technical quality of diabetes care by primary care physicians: the Japan Diabetes Outcome Intervention Trial-2 (J-DOIT2). Diabet Med 2016;33:599-608.
Article PubMed PMC PDF
51. Ueki K, Sasako T, Okazaki Y, Miyake K, Nangaku M, Ohashi Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int 2021;99:256-66.
Article PubMed
52. Sasako T, Ueki K, Miyake K, Okazaki Y, Takeuchi Y, Ohashi Y, et al. Effect of a multifactorial intervention on fracture in patients with type 2 diabetes: subanalysis of the J-DOIT3 Study. J Clin Endocrinol Metab 2021;106:e2116-28.
Article PubMed PMC PDF
53. Sasso FC, De Nicola L, Carbonara O, Nasti R, Minutolo R, Salvatore T, et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 2006;29:498-503.
Article PubMed PDF
54. Sasso FC, Chiodini P, Carbonara O, De Nicola L, Conte G, Salvatore T, et al. High cardiovascular risk in patients with type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate: the NID-2 Prospective Cohort Study. Nephrol Dial Transplant 2012;27:2269-74.
Article PubMed
55. Sasso FC, Marfella R, Pagano A, Porta G, Signoriello G, Lascar N, et al. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study. Acta Diabetol 2015;52:239-47.
Article PubMed PDF
56. Sasso FC, Lascar N, Ascione A, Carbonara O, De Nicola L, Minutolo R, et al. Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy: a multicenter prospective 8 years follow up study. Cardiovasc Diabetol 2016;15:147.
Article PubMed PMC PDF
57. Shikata K, Haneda M, Koya D, Suzuki Y, Tomino Y, Yamada K, et al. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): rationale and study design. Diabetes Res Clin Pract 2010;87:228-32.
Article PubMed
58. Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Res Clin Pract 2011;93:328-36.
Article PubMed
59. Crasto W, Morrison AE, Gray LJ, John E, Jarvis J, Brela J, et al. The Microalbuminuria Education Medication and Optimisation (MEMO) study: 4 years follow-up of multifactorial intervention in high-risk individuals with type 2 diabetes. Diabet Med 2020;37:286-97.
Article PubMed PDF
60. Zhao XH, Xu ZR, Zhang Q, Gu HF, Yang YM. Effect of intensive multifactorial treatment on the intima-media thickness of large arteries in patients with new-onset type 2 diabetes mellitus. J Zhejiang Univ Sci B 2012;13:378-85.
Article PubMed PMC PDF
61. Yang Y, Yao JJ, Du JL, Bai R, Sun LP, Sun GH, et al. Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese. Diabetes Care 2013;36:978-84.
PubMed PMC
62. Shi C, Men L, Yu C, Yao J, Bai R, Yang Y, et al. Atherosclerosis associated with dynamic inflammation changes after multifactorial intervention in short-duration type 2 diabetes: a randomized, controlled, 10-year follow-up trial. J Diabetes Complications 2017;31:1286-92.
Article PubMed
63. Tripolt NJ, Narath SH, Eder M, Pieber TR, Wascher TC, Sourij H. Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2014;13:95.
Article PubMed PMC PDF
64. Shi C, Fang X, Yang Y, Bai R, Yu S, Sun G, et al. Intensive multifactorial intervention improved renal impairment in short-duration type 2 diabetes: a randomized, controlled, 7-year followup trial. J Diabetes Complications 2020;34:107468.
Article PubMed
65. Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care 2009;32:977-82.
PubMed PMC
66. Araki A, Iimuro S, Sakurai T, Umegaki H, Iijima K, Nakano H, et al. Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial: study design, baseline characteristics and effects of intervention. Geriatr Gerontol Int 2012;12 Suppl 1:7-17.
Article PubMed
67. Solomon CG. Reducing cardiovascular risk in type 2 diabetes. N Engl J Med 2003;348:457-9.
Article PubMed
68. Sasako T, Kadowaki T, Ueki K. ADDITION-Europe: the first decade and beyond. Lancet Diabetes Endocrinol 2019;7:891-3.
Article PubMed
69. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
Article PubMed
70. Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010;53:419-28.
Article PubMed PMC
71. Chan JCN. How can we optimise diabetes care in real-world practice? Lancet Diabetes Endocrinol 2017;5:927-9.
Article PubMed
72. Araki E, Senokuchi T, Furukawa N. Impacts of tight multifactorial intervention in patients with type 2 diabetes: implications from the Japan Diabetes Outcome Intervention Trial 3. J Diabetes Investig 2018;9:1022-4.
Article PubMed PMC PDF
73. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
Article PubMed
74. Hayward RA, Reaven PD, Emanuele NV; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:978.
Article PubMed
75. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, et al. Intensive glucose control in patients with type 2 diabetes: 15-year follow-up. N Engl J Med 2019;380:2215-24.
Article PubMed PMC
76. Sasako T, Yamauchi T. Addressing screams for evidence on renoprotection by GLP-1 receptor agonists. Kidney Int 2022;101:222-4.
Article PubMed
77. Sasako T, Yamauchi T. Clinical trials in participants with type 2 diabetes undertaken in Japan. J Jpn Diabetes Soc 2022;65:518-21.
78. Huang ES. Management of diabetes mellitus in older people with comorbidities. BMJ 2016;353:i2200.
Article PubMed PMC
79. Neuen BL, Young T, Heerspink HJ, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845-54.
Article PubMed
80. Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. Lancet Diabetes Endocrinol 2020;8:192-205.
Article PubMed
81. Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet 2018;391:2430-40.
Article PubMed
82. Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021;9:165-73.
Article PubMed PMC
83. Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001- 2010: report of Committee on Causes of Death in Diabetes Mellitus. Diabetol Int 2017;8:117-36.
Article PubMed PMC PDF
84. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998;137 Suppl:S65-73.
Article PubMed
85. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.
Article PubMed
86. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 2019;7:385-96.
Article PubMed
87. Roussel R, Steg PG, Mohammedi K, Marre M, Potier L. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: a perspective on glucose-lowering interventions. Diabetes Obes Metab 2018;20:238-44.
Article PubMed PDF
88. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102.
Article PubMed PMC